Paratek Pharmaceuticals, Inc. (PRTK) Financial Statements (2024 and earlier)

Company Profile

Business Address 75 PARK PLAZA
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:34,20095,500125,200215,400292,800151,700
Cash and cash equivalents34,24880,367105,157102,30246,98735,416
Short-term investments  15,10720,005113,077203,364116,307
Other undisclosed cash, cash equivalents, and short-term investments(48)26382142,449(23)
Restricted cash and investments125125891324266162
Receivables78,03833,11715,7339,5832495,889
Inventory, net of allowances, customer advances and progress billings16,56511,02014,55511,579  
Inventory16,56511,02014,55511,579  
Other undisclosed current assets7,91412,3387,7386,468(38,072)2,735
Total current assets:136,842152,100164,117243,354255,243160,486
Noncurrent Assets
Inventory, Noncurrent31,31427,767    
Operating lease, right-of-use asset1,7821,7572,0102,514
Property, plant and equipment6167949641,2271,1731,711
Long-term investments and receivables     42,487 
Long-term investments     42,487 
Intangible assets, net (including goodwill)829829829829829971
Goodwill829829829829829829
Intangible assets, net (excluding goodwill)      142
Restricted cash and investments  125 3,007249250
Other noncurrent assets1,1554978,933148211280
Total noncurrent assets:35,69631,76912,7367,72544,9493,212
TOTAL ASSETS:172,538183,869176,853251,079300,192163,698
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities36,51828,84022,63920,81215,22514,629
Accounts payable5,3085,3941,8134,1162,0903,555
Accrued liabilities31,21023,44620,82616,69613,13511,074
Debt      
Other liabilities8702,4571,3143,388  
Other undisclosed current liabilities     2,4842,160
Total current liabilities:37,38831,29723,95324,20017,70916,789
Noncurrent Liabilities
Long-term debt and lease obligation256,946255,736252,018262,823228,95959,186
Long-term debt, excluding current maturities256,946254,428250,474260,728228,95959,186
Liabilities, other than long-term debt49,24624,6233,1423,7035,9465,245
Accounts payable and accrued liabilities45,32521,846    
Other liabilities2,4532,7773,1423,7035,9465,174
Operating lease, liability1,4681,3081,5442,095
Business combination, contingent consideration, liability      71
Total noncurrent liabilities:306,192280,359255,160266,526234,90564,431
Total liabilities:343,580311,656279,113290,726252,61481,220
Equity
Equity, attributable to parent(171,042)(127,787)(102,260)(39,647)47,57882,478
Common stock565246403228
Additional paid in capital759,351739,053705,489671,497630,142552,720
Accumulated other comprehensive income (loss)  (9)474(128)(158)
Accumulated deficit(930,449)(866,883)(807,799)(711,258)(582,468)(470,112)
Total equity:(171,042)(127,787)(102,260)(39,647)47,57882,478
TOTAL LIABILITIES AND EQUITY:172,538183,869176,853251,079300,192163,698

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues160,268130,16246,92416,54417,11712,616
Revenue, net12,616
Cost of revenue(23,056)(21,535)(8,651)(3,484)  
Gross profit:137,212108,62738,27313,06017,11712,616
Operating expenses(183,421)(149,757)(113,777)(128,689)(121,273)(97,780)
Other undisclosed operating income     71584
Operating loss:(46,209)(41,130)(75,504)(115,629)(104,085)(84,580)
Nonoperating income819541,5713,5743,2161,343
Investment income, nonoperating752661,5153,5743,2601,377
Other nonoperating income (expense)67(12)56 (44)(34)
Interest and debt expense(18,119)(17,408)(22,608)(16,403)(10,985)(5,079)
Loss from continuing operations before equity method investments, income taxes:(63,509)(58,484)(96,541)(128,458)(111,854)(88,316)
Other undisclosed loss from continuing operations before income taxes    (31)  
Loss from continuing operations before income taxes:(63,509)(58,484)(96,541)(128,489)(111,854)(88,316)
Income tax expense(57)(600) (301)(502)(753)
Other undisclosed loss from continuing operations      
Loss from continuing operations:(63,566)(59,084)(96,541)(128,790)(112,356)(89,069)
Loss before gain (loss) on sale of properties:(59,084)(96,541)(128,790)(112,356)(89,069)
Net loss available to common stockholders, diluted:(63,566)(59,084)(96,541)(128,790)(112,356)(89,069)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(63,566)(59,084)(96,541)(128,790)(112,356)(89,069)
Other comprehensive income (loss) 9(13)(70)20230(142)
Other undisclosed comprehensive income      
Comprehensive loss:(63,557)(59,097)(96,611)(128,588)(112,326)(89,211)
Other undisclosed comprehensive income, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(63,557)(59,097)(96,611)(128,588)(112,326)(89,211)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: